Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Voclosporin ophthalmic - Aurinia Pharmaceuticals

Drug Profile

Voclosporin ophthalmic - Aurinia Pharmaceuticals

Alternative Names: Luveniq; LX 211; LX 212; LX 214

Latest Information Update: 23 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isotechnika
  • Developer Aurinia Pharmaceuticals; Lux Biosciences
  • Class Anti-inflammatories; Antipsoriatics; Ciclosporins; Eye disorder therapies; Immunotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Calcineurin inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dry eyes
  • Discontinued Blepharitis; Uveitis

Most Recent Events

  • 11 Jul 2018 Phase-II clinical trials in Dry eyes in USA (Opthalmic)
  • 22 Jun 2018 Aurinia Pharmaceuticals has patent protection for voclosporin ophthalmic solution
  • 27 Oct 2017 Phase I development is ongoing for Dry eyes in US (Opthalmic) (Aurinia Pharmaceuticals pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top